The Chinese startup has released an image-generation model called Janus-Pro, aiming to take on US rivals DALL-E 3 and Stable ...

Just moments after knocking ChatGPT out of the top spot in the App Store for most downloaded free apps, the company released ...

After an extended bull run, the S&P 500 as a whole is expensively priced based on valuation metrics. So the usual chorus of warnings that the stock market is overvalued is getting louder.

The stock has now tumbled 20.1% over the past three months, while the S&P 500 has eased 0.4%. Mounjaro and Zepbound sales disappoint, and Eli Lilly’s stock is dropping Eli Lilly’s stock was ...

Greg Biffle has confirmed that he'd be in attendance at the 2025 Daytona 500, be it as a racer or a spectator. The former NASCAR driver, who garnered immense respect and praise for his heroic ...

Management attributed this lowered guidance to the slowed sales growth of its tirzepatide products in the fourth quarter — diabetes drug Mounjaro added $3.5 billion, while obesity drug Zepbound ...

Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls in sales could portend weaker long-term potential for this market. Lilly is positioned to remain the ...

The Standard & Poor’s 500 rose 0.1% as three out of every four ... in Lilly’s revenue for its Mounjaro diabetes treatment, Zepbound obesity injections and other products in the incretin ...

Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates. It was the second consecutive miss for the two closely watched ...

(Reuters) -Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed ...

Jaque Silva / NurPhoto via Getty Images U.S. equities ... stock in the S&P 500 when the drugmaker predicted fourth-quarter sales of its blockbuster drugs Zepbound and Mounjaro will come in below ...

Eli Lilly expects about $3.5 billion in revenue for its diabetes treatment Mounjaro and $1.9 billion for its obesity drug Zepbound. CEO Dave Ricks told CNBC that the company has "tons of supply ...